PERISCOPE vs Regard
Regard goes to a health system that wants the whole chart read for missed diagnoses. The vendor says it reviews 100% of the chart, and a demo animation shows Epic with FHIR R4. Its ONC certification is dated May 2, 2024, and the homepage names Banner Health and Main Line Health among customers. The vendor also sells it to finance teams for HCC capture and denial prevention.
PERISCOPE predicts bacterial infection risk 7 and 30 days after surgery from pre- and intra-operative EHR data. A surgical quality lead is the likely buyer, and Deventer Ziekenhuis and Amsterdam UMC give testimonials on the vendor's page. A retrospective study across three hospitals, with two authors affiliated with the vendor, reported 30-day AUROC of 0.82, 0.82 and 0.91.
A surgical quality lead looks at PERISCOPE, while the documentation and coding team that wants diagnoses surfaced from the chart looks at Regard. openFDA lists no 510(k) under Healthplus.ai, and funding coverage describes its US launch and FDA clearance as goals.
Decision support · Reviewed November 2, 2026
When to pick each one
PERISCOPE
- Postoperative infection risk at 7 and 30 days
- CE-marked Class IIa under EU MDR
- Vendor puts implementation at 8 to 12 weeks
Regard
- Suggests diagnoses from the whole chart
- Epic FHIR R4 shown in vendor demo
- Also sold for HCC capture and denial prevention
Score
Each row shows points earned of points available under the published rubric.
PERISCOPE
15of 100
Regard
9of 100
| Dimension | PERISCOPE | Regard | Difference |
|---|---|---|---|
| FDA clearance | 0 / 12 | 0 / 12 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 5.6 | 1.7 / 5.6 | -1.7 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 1.9 / 4.8 | -1.9 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 8.4 / 21 | 0 / 21 | +8.4 |
| RCT / meta-analysis / systematic review | 0 / 9 | 0 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 1.3 / 2.5 | 1.3 / 2.5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
PERISCOPE
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Regard
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
PERISCOPE
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names PERISCOPE.
Regard
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | PERISCOPE | Regard |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Epic |
| Founded | n/a | n/a |
| HQ | NL | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.